Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Kathleen N. Moore , Nicoletta Colombo , Giovanni Scambia , Kathleen N. Moore , Nicoletta Colombo , Giovanni Scambia , Byoung‐Gie Kim , Ana Oaknin , Michael Friedländer , Alla Lisyanskaya , Anne Floquet , Alexandra Léary , Gabe S. Sonke , Charlie Gourley , Susana Banerjee , Amit M. Oza , Antonio González-Martı́n , Carol Aghajanian , William H. Bradley , Cara Mathews , Joyce F. Liu , Elizabeth Lowe , Ralph Bloomfield , Paul DiSilvestro
2018 New England Journal of Medicine 2,632 citations

Abstract

The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olaparib than with placebo. (Funded by AstraZeneca and Merck; SOLO1 ClinicalTrials.gov number, NCT01844986 .).

Keywords

OlaparibMedicineOvarian cancerOncologyChemotherapyInternal medicineDiseasePARP inhibitorCancerMaintenance therapyGynecologyPoly ADP ribose polymerasePolymeraseBiologyEnzyme

Affiliated Institutions

Related Publications

Publication Info

Year
2018
Type
article
Volume
379
Issue
26
Pages
2495-2505
Citations
2632
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2632
OpenAlex

Cite This

Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. (2018). Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine , 379 (26) , 2495-2505. https://doi.org/10.1056/nejmoa1810858

Identifiers

DOI
10.1056/nejmoa1810858